Novavax, Inc. : Novavax Announces Management Promotion
05 April 2016 - 6:05AM
GAITHERSBURG, Md., April 04, 2016 (GLOBE NEWSWIRE)
-- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company
focused on the discovery, development and commercialization of
recombinant nanoparticle vaccines and adjuvants, today announced
that Iksung Cho has been named Vice President, Biostatistics.
Mr. Cho joined Novavax in December 2015 as
Executive Director, Biostatistics with responsibility for
coordinating statistical and statistical programming activities for
vaccine candidates in various stages of clinical development. Prior
to joining Novavax he was Senior Statistician at PATH, an
international nonprofit organization that aims to accelerate
innovation across vaccines, drugs, diagnostics, devices and system
and service innovations.
Mr. Cho's experience includes positions of
increasing responsibility in biostatistics and data management at
Aviron, Merck and MedImmune, where he was Vice President of Global
Biostatistics. He earned Master's degrees in both statistics and
applied mathematics from Virginia Polytechnic and State University
and completed graduate studies in mathematics.
"Iksung has rapidly become a critical part of our
team," said Gregory M. Glenn, M.D., President, Research and
Development. "We expect to leverage his deep experience in
biostatistics to evaluate important data readouts from the pivotal
Phase 3 Resolve trial of our RSV F Vaccine in older adults and the
Phase 2 rollover trial in older adults later this year."
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
vaccine company committed to delivering novel products to prevent a
broad range of infectious diseases. Its recombinant nanoparticles
and Matrix-M(TM) adjuvant technology are the foundation for
groundbreaking innovation that improves global health through safe
and effective vaccines.
Contact: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
ir@novavax.com
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novavax, Inc. via Globenewswire
HUG#1999941
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From May 2023 to May 2024